← Back to Screener
Celcuity Inc. Common Stock (CELC)
Price$125.25
Favorite Metrics
Price vs S&P 500 (26W)145.45%
Price vs S&P 500 (4W)3.92%
Market Capitalization$5.97B
All Metrics
Book Value / Share (Quarterly)$2.08
P/TBV (Annual)2.49x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.18
Price vs S&P 500 (YTD)21.15%
EPS (TTM)$-3.78
10-Day Avg Trading Volume0.69M
EPS Excl Extra (TTM)$-3.78
EPS (Annual)$-3.79
ROI (Annual)-41.91%
Cash / Share (Quarterly)$9.15
ROA (Last FY)-37.95%
EBITD / Share (TTM)$-3.68
ROE (5Y Avg)-78.33%
Cash Flow / Share (Annual)$-3.18
P/B Ratio59.35x
P/B Ratio (Quarterly)45.90x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-35.50x
ROA (TTM)-52.68%
EPS Incl Extra (Annual)$-3.79
Current Ratio (Annual)10.55x
Quick Ratio (Quarterly)10.12x
3-Month Avg Trading Volume0.76M
52-Week Price Return1166.36%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.15
52-Week High$125.00
EPS Excl Extra (Annual)$-3.79
CapEx CAGR (5Y)22.57%
Tangible BV CAGR (5Y)33.63%
26-Week Price Return149.43%
Quick Ratio (Annual)10.12x
13-Week Price Return18.14%
Total Debt / Equity (Annual)3.20x
Current Ratio (Quarterly)10.55x
Enterprise Value$6,124.277
Book Value / Share Growth (5Y)12.91%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$9.15
3-Month Return Std Dev52.65%
Net Income / Employee (TTM)$-2
ROE (Last FY)-176.06%
Net Interest Coverage (Annual)-35.50x
EPS Basic Excl Extra (Annual)$-3.79
Total Debt / Equity (Quarterly)3.20x
EPS Incl Extra (TTM)$-3.78
ROI (TTM)-59.59%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$6.17
Price vs S&P 500 (52W)1136.53%
Year-to-Date Return23.79%
5-Day Price Return-0.94%
EPS Normalized (Annual)$-3.79
ROA (5Y Avg)-34.87%
Month-to-Date Return8.17%
Cash Flow / Share (TTM)$-2.73
EBITD / Share (Annual)$-3.68
LT Debt / Equity (Annual)3.20x
ROI (5Y Avg)-37.97%
LT Debt / Equity (Quarterly)3.20x
EPS Basic Excl Extra (TTM)$-3.78
P/TBV (Quarterly)3.58x
P/B Ratio (Annual)45.90x
Book Value / Share (Annual)$2.08
Price vs S&P 500 (13W)17.45%
Beta0.11x
Revenue / Share (TTM)$0.00
ROE (TTM)-203.17%
52-Week Low$9.02
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.29
4.29
4.29
4.29
Industry Peers — Health Services(21)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
CELCCelcuity Inc. Common Stock | — | — | — | -203.17% | $125.25 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $196.11 |
LHLabcorp Holdings Inc. | 25.08x | 7.25% | 9.92% | 10.28% | $266.36 |
DGXQuest Diagnostics Inc. | 21.24x | 11.78% | 14.10% | 13.88% | $191.46 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $85.70 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $60.09 |
VCYTVeracyte, Inc. | 40.04x | 16.01% | 11.17% | 5.33% | $33.03 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $49.47 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $22.42 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.09 |
About
Celcuity is a clinical-stage oncology biotechnology company developing gedatolisib, a dual PI3K/mTOR inhibitor with a differentiated mechanism of action compared to existing therapies. The company's lead program is in Phase 3 development (VIKTORIA-1), evaluating gedatolisib combined with fulvestrant with or without palbociclib for hormone receptor-positive, HER2-negative advanced breast cancer.